These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8193188)

  • 21. [Maintenance therapy in reflux esophagitis].
    Katsoulis S; Fölsch UR
    Z Gastroenterol; 1997 Feb; 35(2):159-61. PubMed ID: 9163230
    [No Abstract]   [Full Text] [Related]  

  • 22. Recent developments in the pathophysiology and therapy of gastroesophageal reflux disease and nonerosive reflux disease.
    Tack J
    Curr Opin Gastroenterol; 2005 Jul; 21(4):454-60. PubMed ID: 15930988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary gastro-oesophageal reflux disease and irritable oesophagus syndrome as causes of recurrent abdominal pain in children.
    Corrado G; Cavaliere M; Frandina G; Rea P; Pacchiarotti C; Capocaccia P; Cardi E
    Ital J Gastroenterol; 1996; 28(8):462-9. PubMed ID: 9032590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group.
    Castell DO; Sigmund C; Patterson D; Lambert R; Hasner D; Clyde C; Zeldis JB
    Am J Gastroenterol; 1998 Apr; 93(4):547-52. PubMed ID: 9576446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiological studies on nitric oxide in the lower esophageal sphincter of patients with reflux esophagitis.
    Tomita R; Tanjoh K; Fujisaki S; Fukuzawa M
    Hepatogastroenterology; 2003; 50(49):110-4. PubMed ID: 12630004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prevalence of reflux oesophagitis among upper endoscopies of Iranian patients.
    Rezailashkajani M; Roshandel D; Shafaee S; Zali MR
    Eur J Gastroenterol Hepatol; 2007 Jun; 19(6):499-506. PubMed ID: 17489061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastroesophageal reflux disease in the older patient: presentation, treatment, and complications.
    Richter JE
    Am J Gastroenterol; 2000 Feb; 95(2):368-73. PubMed ID: 10685737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisapride marketed for use in gastroesophageal reflux disease.
    Clin Pharm; 1993 Dec; 12(12):876, 879. PubMed ID: 8137603
    [No Abstract]   [Full Text] [Related]  

  • 29. [Effect of elevated head position in bed in therapy of gastroesophageal reflux].
    Pollmann H; Zillessen E; Pohl J; Rosemeyer D; Abucar A; Armbrecht U; Bornhofen B; Herz R
    Z Gastroenterol; 1996 Jun; 34 Suppl 2():93-9. PubMed ID: 8767437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of dyspepsia. Management plan aimed at prevention of upper abdominal complaints].
    Haycox A
    Internist (Berl); 1996 Dec; 37(12 Suppl Management):1-4. PubMed ID: 9022388
    [No Abstract]   [Full Text] [Related]  

  • 31. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease.
    Jones MP; Sloan SS; Rabine JC; Ebert CC; Huang CF; Kahrilas PJ
    Am J Gastroenterol; 2001 Jun; 96(6):1711-7. PubMed ID: 11419819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exogenous luminal nitric oxide exacerbates esophagus tissue damage in a reflux esophagitis model of rats.
    Ishiyama F; Iijima K; Asanuma K; Ara N; Yoshitake J; Abe Y; Koike T; Imatani A; Ohara S; Shimosegawa T
    Scand J Gastroenterol; 2009; 44(5):527-37. PubMed ID: 19172433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A new prokinetic drug cisapride: pharmacological properties and clinical potential].
    Sheptulin AA; Muradov NN
    Klin Med (Mosk); 1997; 75(7):53-6. PubMed ID: 9411058
    [No Abstract]   [Full Text] [Related]  

  • 34. Non-erosive and erosive gastroesophageal reflux diseases: No difference with regard to reflux pattern and motility abnormalities.
    Martínek J; Benes M; Hucl T; Drastich P; Stirand P; Spicák J
    Scand J Gastroenterol; 2008; 43(7):794-800. PubMed ID: 18584517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional foregut abnormalities in Barrett's esophagus.
    Stein HJ; Hoeft S; DeMeester TR
    J Thorac Cardiovasc Surg; 1993 Jan; 105(1):107-11. PubMed ID: 8419690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reflux esophagitis patients in Singapore have motor and acid exposure abnormalities similar to patients in the Western hemisphere.
    Ho KY; Kang JY
    Am J Gastroenterol; 1999 May; 94(5):1186-91. PubMed ID: 10235190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esophageal motility in patients with sliding hiatal hernia with reflux esophagitis.
    Ye P; Li ZS; Xu GM; Zou DW; Xu XR; Lu RH
    Chin Med J (Engl); 2008 May; 121(10):898-903. PubMed ID: 18706203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics.
    Fass R
    J Clin Gastroenterol; 2007 Feb; 41(2):131-7. PubMed ID: 17245209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA approved. New drug bulletin: Cisapride and Dornase alfa.
    RN; 1994 Apr; 57(4):39-42. PubMed ID: 8165421
    [No Abstract]   [Full Text] [Related]  

  • 40. [Gastroesophageal reflux].
    Schwizer W; Fried M
    Ther Umsch; 1997 Nov; 54(11):611-6. PubMed ID: 9454361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.